Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AVITA MedicalASX:AVH -3.65%55 Earnings Yield (Joel Greenblatt) % is -27.17% as of Mar. 2026. GuruFocus rates ASX:AVH with a GF Score™ of 55/100 and a GF Value™ of A$3.22 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 848 Medical Devices & Instruments companies, AVITA Medical ranks worse than 82.67% on this metric.
AVITA Medical's Enterprise Value for the quarter that ended in Mar. 2026 was A$213.7 Mil.
AVITA Medical's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was A$-60.1 Mil. AVITA Medical's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was -27.17%.
The historical rank and industry rank for AVITA Medical's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
ASX:AVH'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -98.39 Med: -15.6 Max: -0.39
Current: -23.45
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of AVITA Medical was -0.39%. The lowest was -98.39%. And the median was -15.60%.
ASX:AVH's Earnings Yield (Joel Greenblatt) % is ranked worse than 82.67% of 848
companies
in the Medical Devices & Instruments industry
Industry Median: 0.85
vs ASX:AVH: -23.45
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. AVITA Medical's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
AVITA Medical (ASX:AVH) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
AVITA Medical Earnings Yield (Joel Greenblatt) % Related Terms
AVITA Medical Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for AVITA Medical's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVITA Medical Earnings Yield (Joel Greenblatt) % Chart
For the Medical Devices subindustry, AVITA Medical's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVITA Medical Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where AVITA Medical's Earnings Yield (Joel Greenblatt) % falls into.
AVITA Medical Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
AVITA Medicals Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
AVITA Medical's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$-60.1 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -27.17% mean?
AVITA Medical (ASX:AVH) has a Earnings Yield (Joel Greenblatt) % of -27.17% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on AVITA Medical and its competitors. According to the industry distribution chart, AVITA Medical ranks #701 out of 848 companies in the Medical Devices & Instruments industry, placing it in the top 82.7%.
Is AVITA Medical's Earnings Yield (Joel Greenblatt) % too high?
AVITA Medical's current Earnings Yield (Joel Greenblatt) % is -27.17%. Based on the distribution chart, AVITA Medical ranks #701 out of 848 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, AVITA Medical has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AVITA Medical's Earnings Yield (Joel Greenblatt) % compare to OWLT and CVRX?
According to the Medical Devices & Instruments industry distribution chart, AVITA Medical ranks #701 out of 848 companies for Earnings Yield (Joel Greenblatt) %. This places AVITA Medical in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 0.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.85, based on 848 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on AVITA Medical and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AVITA Medical's current Earnings Yield (Joel Greenblatt) % is -27.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AVITA Medical stock overvalued right now?
Based on GuruFocus' analysis, AVITA Medical (ASX:AVH) is currently considered Possible Value Trap. The stock's GF Value™ is A$3.22, compared to a current price of A$1.32 — trading 59% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -27.17%. AVITA Medical's overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For AVITA Medical (ASX:AVH), the current Earnings Yield (Joel Greenblatt) % is -27.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AVITA Medical (ASX:AVH) Overvalued in 2026?
Based on GuruFocus' analysis, AVITA Medical stock appears to be undervalued.
The current stock price of A$1.32 is trading 59% below its estimated GF Value™ of A$3.22.
GuruFocus considers AVITA Medical to be Possible Value Trap.
Key valuation signals for ASX:AVH:
Earnings Yield (Joel Greenblatt) %: -27.17%
GF Value™: A$3.22 vs. price of A$1.32 (59% below fair value)
No single metric tells the full story. See the ASX:AVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
55GF Score
Get the complete analysis for ASX:AVH
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVH has been successfully added to your 
